Wiley Blackwell

SHERPA: Unknown

People

  1. Herr
    Herr
  2. Motzer
    Motzer
  3. Brennan
    Brennan
  4. Shah
    Shah
  5. Danishefsky
    Danishefsky
  6. Vickers
    Vickers
  7. Russo
    Russo
  8. Shaha
    Shaha
  9. Eastham
    Eastham
  10. Scardino
    Scardino

Groups

  1. Department of Medicine (1537)
  2. Surgery (1247)
  3. Solid Tumor Oncology Division (893)
  4. Survivorship Research (827)
  5. GSK Faculty (671)
  6. Population Sciences Research Program (628)
  7. Sloan Kettering Institute Faculty (612)
  8. Department of Pathology and Laboratory Medicine (555)
  9. Epidemiology and Biostatistics (494)
  10. Center for Hematologic Malignancies (437)
Search Within
Formats
  1. Journal Article (3530)
  2. Meeting Abstract (684)
  3. Review (200)
  4. Book Section (107)
  5. Conference Paper (94)
  6. Editorial (91)
  7. Research Letter (35)
  8. Guidelines (28)
  9. Correspondence (25)
  10. Miscellaneous (5)
  11. Book Whole (3)
Groups
  1. Department of Medicine (1537)
  2. Surgery (1247)
  3. Solid Tumor Oncology Division (893)
  4. Survivorship Research (827)
  5. GSK Faculty (671)
  6. Population Sciences Research Program (628)

More Groups

People
  1. Harry Herr (92)
  2. Robert Motzer (87)
  3. Murray Brennan (86)
  4. Jatin Shah (77)
  5. Andrew Vickers (74)
  6. Samuel Danishefsky (74)

More People

Years
  1. 2025 (147)
  2. 2024 (192)
  3. 2023 (261)
  4. 2022 (186)
  5. 2021 (221)
  6. 2020 (183)

More Years

Publications
  1. Cancer (1461)
  2. Journal of Surgical Oncology (376)
  3. BJU International (338)
  4. Hematological Oncology (199)
  5. Histopathology (158)
  6. EMBO Journal (132)

More Publications

Results (4802)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Genomic correlates of radiosensitivity in diffuse large B cell lymphoma
    Meeting Abstract

    Sarkar, R. R.; Ma, J.; Wijetunga, N. A.; Salles, G.; Joffe, E.; Imber, B.; Yahalom, J.
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Mature T and NK cell lymphomas classified according to 2016 WHO classification. A report of 741 cases registered in the International Prospective T‐cell Project 2.0
    Meeting Abstract

    Manni, M.; Chiattone, C. S.; Prince, M. H.; Pavlovsky, A.; Tomuleasa, C.; Miranda, E.; Kriachok, I.; Hawkes, E. A.; Fiad, L.; Hitz, F.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Genetic alterations in follicular lymphoma predict response to very low dose radiotherapy
    Meeting Abstract

    Wijetunga, N. A.; Lebow, E.; Chan, A.; Lee, J.; Fregonese, B.; Hajj, C.; Cedarquist, G.; Hubbeling, H.; Ma, J.; Sarkar, R.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Enhancing T‐cell responses to GCB‐like lymphomas with immune‐checkpoint‐blockade‐based therapies
    Meeting Abstract

    Serganova, I.; Bucktrout, R.; Isshiki, Y.; Sarapulov, A.; Santella, A.; Rodriguez, M.; Chakraborty, S.; Brunschvig, S.; Qualls, D.; Vardhana, S.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Lisocabtagene maraleucel (LISO‐CEL) versus standard of care (SOC) as second‐line therapy in large B‐cell lymphoma (TRANSFORM study): Subgroup analyses by prior therapy response
    Meeting Abstract

    Nastoupil, L. J.; Kamdar, M.; Chavez, J. C.; Ghesquieres, H.; Ghosh, M.; Holmes, H.; López‐Guillermo, A.; Martínez‐López, J.; Novak, U.; Ribrag, V.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Very low dose radiation therapy for indolent lymphoma: Comparing "Big Boom" (4GY × 1) versus "Boom Boom" (2GY × 2)
    Meeting Abstract

    Hajj, C.; Lee, J.; Boe, L.; Fregonese, B.; Lebow, E.; Wijetunga, N. A.; Hubbeling, H.; Tringale, K.; Freret, M.; Imber, B.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Lisocabtagene maraleucel (LISO‐CEL) versus standard of care (SOC) as second‐line therapy in large B‐cell lymphoma (TRANSFORM study): Subgroup analyses by prior therapy response
    Meeting Abstract

    Tobin, J. W.; Jurinovic, V.; Tsang, H.; Roos, D.; Tsang, R.; Macann, A.; Davis, S.; Christie, D.; Law, S.; Nath, K.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Long‐term follow-up of multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in previously untreated patients with CLL/SLL
    Meeting Abstract

    Soumerai, J. D.; Dogan, A.; Seshan, V.; Flaherty, K.; Carter, J.; Hochberg, E.; Barnes, J. A.; Abramson, J. S.; Hamilton, A. M.; Noy, A.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • AFM13 in patients with CD30 positive relapsed or refractory (R/R) peripheral T cell lymphoma (PTCL): Results from the phase 2 redirect study
    Meeting Abstract

    Kim, W. S.; Shortt, J.; Zinzani, P. L.; Mikhaylova, N.; Marin‐Niebla, A.; Radeski, D.; Ribrag, V.; Domenech, E. D.; Sawas, A.; Alexis, K.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • High complete metabolic response rates with epcoritamab + R‐CHOP in previously untreated (1L) high‐risk DLBCL, including double‐hit/triple‐hit: EPCORE NHL‐2 update
    Meeting Abstract

    Falchi, L.; Clausen, M. R.; Offner, F.; de Vos, S.; Brody, J.; Linton, K. M.; Snauwaert, S.; Cordoba, R.; Wu, J.; Bykhovski, I.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save